

# A comprehensive characterization of blood group antigen variants in the Middle Eastern population genomes - Insights into genetic epidemiology

Mercy Rophina<sup>1,2</sup>, Kavita Pandhare<sup>1,2</sup>, Vinod Scaria<sup>1,2§</sup>

<sup>1</sup>CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), Mathura Road, Delhi 110025, INDIA

<sup>2</sup>Academy of Scientific and Innovative Research (AcSIR), CSIR-HRDC Campus, Sector 19, Kamlia Nehru Nagar, Ghaziabad, Uttar Pradesh 201002, INDIA

<sup>3</sup>Present address: Vishwanath Cancer Care Foundation (VCCF), Neelkanth Business Park, West Mumbai, 400086 India

§Address for correspondence

**Corresponding author Email:**

Dr. Vinod Scaria - [vinods@igib.in](mailto:vinods@igib.in) (Scaria V) ; Tel: 91-11-29879 109

## Key points

- Large scale Middle Eastern population sequencing datasets including *The Greater Middle Eastern Variome, Genomes and exomes from Qatar and the Iranome* datasets were used in the study.
- A total of **2828** exomes and **88** genomes were analyzed accounting for a total of **18717** unique human blood group related variants.
- **2443** exonic variants were extracted which systematically included **1505** non-synonymous variants, **766** synonymous variants, **50** stopgain variants and **3** stop loss variants.
- Blood group associated variants identified in the study are provided as a comprehensive online repository - **alnasab**, *Alleles and antigens in Arab and Persian populations associated with blood groups*. The resource is accessible at <https://clingen.igib.res.in/alnasab/>

## Abstract

### **Background**

The Middle Eastern population is characterized by increased prevalence of various Mendelian disorders owing to increased rates of consanguinity. Especially in disease conditions which require chronic transfusion support, it becomes important to know the blood group characteristics of potential donors to increase the likelihood of transfusion success. As there prevails a gap in knowledge about the population specific overall blood antigen profiles, this study seeks to utilize next generation sequencing datasets to unravel the comprehensive landscape of clinically significant minor blood group alleles in the middle eastern population.

### **Methods**

This study utilizes the genetic variation data from a range of public datasets including the Greater Middle East Variome, the Qatar genome and exomes and the Iranome datasets to estimate the genotypic and phenotypic frequencies of blood group alleles in the Middle Easterners. The estimated frequencies were duly compared with major global populations to identify significant similarities or differences if any.

### **Results**

A total of 77 unique ISBT approved blood group alleles were found commonly in all datasets. 8 variants (rs8176058, rs1058396, rs565898944, rs28362692, rs2071699, rs34783571, rs60322991 and rs57467915) belonging to KELL, KIDD, COLTON, H, JUNIOR and LANGEREIS blood groups were found clinically significant with previously reported evidence on transfusion complications. 730 variants were found to span exonic or splicing regions out of which 70 were predicted to be potentially deleterious by at least four computational tools.

### **Conclusions**

This study serves first of its kind to extensively characterize the known and novel blood alleles in the Middle Easterners. A comprehensive user-friendly online resource named **alnasab - Alleles and antigens in Arab and Persian populations associated with blood groups** was also developed as a dependable reference for future transfusion research. The resource is accessible at <https://clingen.igib.res.in/alnasab/>

## Introduction

Blood group antigens are genetically encoded and currently encompass 44 blood group systems, encoding a total of 349 antigens mapping to 50 genes as recognized and approved by the International Society for Blood Transfusion (ISBT). Complications accompanying blood transfusion events are often induced by blood products which escape serological vigilance. Research over the past decade has widened the scope of genomics in

immunohematology by highlighting the existence of geographical and ethnicity based differences in blood genotype and phenotype frequencies. (1), (2), (3).

The Middle Eastern region situated between Africa, Europe and South Asia is the abode of a population which has been central to our understanding of human evolution, history and migration (4), (5), (6), (7). Encompassing about 17 countries with an estimated population of around 411 million, this region has often remained underrepresented in large global population scale genomic studies. However, with a recent spurt in interest, various population scale sequencing projects have been undertaken aimed at understanding the genomic diversity and architecture of the Arab populations.(8), (9), (10), (11), (12).

Only a limited number of studies have investigated the prevalence of blood group antigens in Middle Eastern populations, primarily focusing on the ABO and RH systems along with few other clinically significant minor blood groups (13), (14), (15), (16), (17). However, these studies have been limited by their use of standard serological testing or medium throughput molecular typing techniques, and therefore there is a paucity of a comprehensive population-specific molecular blood group profile.

It is well established that genetic disorders are a significant burden in the Middle East owing to their increased rates of consanguinity. This has resulted in high prevalence of various autosomal recessive disorders. In particular, genetic blood disorders including Sickle cell disease (SCD) and  $\beta$ -thalassemia, the most common hemoglobinopathies have been reported to substantially contribute to the disease burden of this population (18), (19). A review estimated that the overall incidence and prevalence of SCD in Middle Eastern countries ranged from approximately 0.004% - 2.1% respectively (20). Such inherited blood disorders owing to their chronic nature tend to impose heavy medical, emotional and financial burden. Although the overall burden of such illnesses encompassing various medical aspects of the disease largely remain uncharacterized in Middle Eastern countries, conditions like thalassemia major (TM) and SCD demand long term transfusion therapy.

In recent years, there have been systematic efforts to determine the blood group phenotypes of regular blood donors visiting donation centers in the United Arab Emirates. Advancements in next generation sequencing techniques would undoubtedly enable the large population scale deployment of such efforts in the region. The availability of numerous public Middle Eastern genomic datasets encouraged us to computationally decipher the blood antigen profiles of Middle Easterners as previously described by Schoeman et al in 2019.

In this study we aim to compile a comprehensive collation of blood alleles prevailing in the middle eastern population along with a systematic comparison with other major population datasets including the 1000 Genomes Project and gnomAD. In addition, we developed a user-friendly online resource *alnasab - Alleles and antigens in Arab and Persian populations associated with blood groups* which is a comprehensive catalog of genetic variants associated with human blood group systems identified in Middle Easterners. The resource is accessible online at <https://clingen.igib.res.in/alnasab/>

## Materials and methods

### *Population scale genomic datasets*

Whole genome and whole exome sequencing datasets generated by population specific studies in the Greater Middle Eastern region were compiled and used for the analysis. This includes data from the Greater Middle East Variome (21), The Qatar genome and exomes (10) and the Iranome (9) genome projects. These accounted for a total of 2828 high quality exomes and 88 genomes (GME : 1111 exomes; Qatar : 88 genomes and 917 exomes ; Iranome : 800 exomes), encompassing 689299, 20159694 and 1575702 total genetic variants respectively. The population scale data is a collation of major ethnic groups of the middle eastern region including North Western Africa (NWA), North East Africa (NEA), Arabian Peninsula (AP), Turkish Peninsula (TP), Persia and Pakistan (PP), Syrian Desert (SD), Qatari subgroups and Iranian Arabs, Azeris, Baluchs, Kurds, Lurs, Turkmen and Persians. All the datasets correspond to human genome 19 (GRCh37/hg19) assembly. Genetic variations were retrieved from the variant call format (VCF) files and were used for further analyses.

### *Human blood group related alleles and variations*

Clinically approved genomic coordinates of 50 genes associated with 43 human blood group systems and 2 erythroid specific transcription factors were fetched from Locus Genomic Reference (LRG) (22) and were used for analysis as described previously (23). There exists a handful of public resources that provide comprehensive collection of human blood alleles and antigens including the International Society of Blood Transfusion (ISBT) (24), The Blood Group Antigen Gene Mutation Database (dbRBC) (25), ErythroGene (26) RhesusBase (27), Blood Antigens (28,29) and BGvar (30). A comprehensive list of approved and predicted human blood group alleles were retrieved in a pre-formatted template (30) and was used as the reference data for further allele matching procedures.

### *Data processing and variant annotations*

Primary analysis involved the filtering of all genetic variations spanning the LRG approved genomic coordinates of blood group genes and erythroid specific transcription factors. Subsequently, the filtered variants were systematically annotated for their functional consequences from a range of computational tools including SIFT (31), Polyphen (32), LRT, MutationTaster, Mutation Assessor (33), FATHMM (34), PROVEAN (35), CADD (36), GERP (37), PhyloP (38) and PhastCons using ANNOVAR (v. 2018-04-06) (39).

### *Known and novel blood group alleles/variants identification*

Secondary stages of variant analyses involved the filtering and identification of well known and novel blood group alleles. Reference dataset was used to match all the variants which already had a known associated blood phenotype and reference genome nomenclature was conferred to those blood group systems with no blood group associated variants. In addition, potentially novel and rare blood group variants were also filtered and analyzed. A variant was deemed potentially novel if it lacked previous literature reports and SNP identification number (dbSNP ID). Variants with minor allele frequencies (MAF) < 5% were also filtered and checked for their association with blood group related phenotypes. A complete schematic representation of the workflow is shown in **Figure 1**.

### *Prediction of blood phenotypes in Qatari subpopulations*

The publicly available genomic data of 1005 Qatari individuals comprising 5 major subpopulations were analyzed in the study to decipher the pattern of distribution of blood

phenotypes among the Qatari subpopulations. The variant call file was systematically subsetted into each subpopulation using VCFTools (40). Bespoke scripts were used to generate the number of samples with homozygous and heterozygous genotypes. Similarities and distinct differences in blood alleles and phenotype frequencies were studied. Minor allele frequencies were compared among the subpopulations and statistical significance was observed using Fisher's exact test with a p-value < 0.05.

#### *Estimation and systematic comparison of blood allele frequencies*

Blood group associated variants filtered from all the datasets were systematically compiled in variant call or annotated formats along with their genotype information. Allele frequencies were estimated using PLINK {ref}. In addition, allele frequencies of the variants were fetched from major global population datasets including 1000 Genomes project {ref}, Exome Aggregation Consortium (ExAC v.0.3) {ref} and Genome Aggregation Database (gnomAD) {ref} and were used for comparison. Frequency of the filtered alleles among the subpopulations were also calculated.

#### *Identification of clinically significant and actionable blood group alleles*

Variants with known blood group associated phenotypes filtered from the datasets were further checked for their clinical relevance in transfusion procedures and in pregnancy settings. Literature databases and public resources like Pubmed and Google scholar were systematically queried to retrieve relevant clinically significant evidence of alleles.

#### *Compendium of Greater Middle East blood group variants - Database architecture*

The filtered variants were compiled into a preformatted mastersheet and annotations were duly mapped. The variant data and corresponding annotations were transformed to JavaScript Object Notation format and ported onto MongoDB 3.4.1. The user-friendly web interface for querying the database was coded in PHP 7.0, AngularJS, HTML, Bootstrap 4 and CSS. The web server was configured in Apache HTTP server.

## **Results**

#### *Overview of blood group alleles in Greater Middle East*

We retrieved a total 18717 unique variants mapping to 50 human blood group genes, out of which 1697, 15140 and 3496 variants were from the Greater Middle East Variome, The Qatar genome and the Iranome datasets respectively. **Supplementary Table 1** provides a comprehensive summary of all the variant counts in blood group genes fetched from the above mentioned datasets. Of the variants, 2428 and 15 variants were found across exonic and splicing regions respectively. Of these, there were 1505 non synonymous SNVs, 766 synonymous SNVs, 50 stop gain and 3 stop loss variants. Variant summary and functional classifications across the datasets are schematically represented in **Figure 2**.

#### *Characterization of genetic variations in human blood group genes*

Of the variants which mapped to the 50 blood group genes, a total of 147, 110 and 112 variants were previously shown to be associated with blood group related phenotypes in GME, Qatar and Iranome datasets respectively. Of these variants, a total of 77 unique variants belonging to 20 blood group systems were overlapping in all three datasets used in this study. The details of the variants along with their frequencies are tabulated in **Table 1**.

**Figure 3** illustrates the distribution of these variants and their corresponding allele frequencies in various datasets. Forty-six (46) of the total 77 variants were SNVs mapping back to 16 blood groups and the rest were combination mutations for which blood phenotypes could not be predicted. Phenotypes were reported the same as that of the reference genome (hg19) nomenclature for the rest blood group systems as previously described (41), (23). **Table 2** summarizes the phenotypes of the variants and their corresponding zygosity information across the datasets. Phenotype frequencies of blood group systems with known blood group associated variants and those with reference genome nomenclature are detailed in **Supplementary Table 2**.

#### *Overview of potentially novel and rare blood group variants*

Variants were systematically classified based on the dbSNP identifiers and were deemed as potentially novel if they lacked one. This analysis revealed a total of 1727 potentially novel unique variants across the datasets, of which 730 were found to span the exonic and splicing regions. Seventy (70) exonic variants which were not reported previously in global population frequencies including 1000 Genomes, gnomAD and EXAC were predicted to be deleterious by at least three or more computational tools. Distribution of these novel variants across different blood group genes along with their corresponding frequencies in the Middle Eastern datasets are summarized in **Supplementary Table 3**. A missense H blood group variant (p. Arg220Leu, chr19:49253880C>A) which was computationally predicted as deleterious, has a couple of alternate variants reported at the same position associated with weak H<sup>+</sup> phenotype (p.Arg220Cys - FUT\*01W.09 and p.Arg220His - FUT\*01W.10). Yet another missense variant predicted from the same blood group (p. Try154Asp, chr19:49254079A>C) possess reported variants at the same amino acid position associated with weak and null H phenotypes (p.Tyr154Cys - FUT\*01N.02, p.Tyr154His - FUT\*01W.o5.01 and p.Tyr154Ter - FUT\*01N.03).

Two missense variants belonging to JUNIOR blood group predicted as deleterious (p.Gly262Glu, chr4:89039317C>T and p.Arg246Leu, chr4:89039365C>A) were found to occur at the same amino acid sites which were reported to be associated with Jr(a-) phenotypes (p.Gly262X - ABCG2\*01N.05 and p.Arg246X - ABCG2\*01N.03 respectively).

#### *Distribution of null and partial/weak antigens*

Weak or partial expression of RBC antigens carries increased risk of hemolytic transfusion reactions as they are often mistyped as antigen-negative. Of the total variants analysed, our study reports 19 variants responsible for weak/partial or null blood group phenotypes. The RHD\*weak D type 4.0 allele (*rs1053355*) was observed in 10 individuals in a homozygous state. This allele, responsible for the weak expression of D antigen, was found to be often mistyped as D- in serological tests (42). In addition, one of the rare low frequency antigens of the RH blood group system, C<sup>w+</sup> (Rh8 - *rs138268848*) was found in about 0.17% of Middle Eastern populations (0.13% in Iranome and 0.36% in GME). This antigen has been reported to have serious transfusion implications including hemolytic disease of the newborn when mismatched (43).

A weak JK\*A allele (JK\*01W.01 - *rs2298720*) of the KIDD blood group system, associated with weakened expression of Jk<sup>a</sup> is found capable of causing alloimmunization when mistyped serologically as Jk<sub>null (44)</sub>, (45). Distribution of this variant is found to vary highly among various global populations with an allele frequency as high as 40.6% in East Asians,

26.8% in South Asians, 18-19% in Latino/Admixed Americans and African/African Americans, 12% in Europeans of Finnish origin, 10% in Ashkenazi Jews to as low as 7% in Middle Easterners, 6% in Europeans of non-Finnish origins and 3% in Amish population. **Supplementary Table 4** enlists the complete details of weak/partial alleles identified in the study dataset.

#### *Clinically significant blood group variants*

The KELL blood group system is significant in the field of transfusion medicine owing to the severe transfusion incompatible reactions induced by its antigens (46). This system comprises over 20 different antigens, of which K1 (K) has been well studied as a strong immunogen capable of causing hemolytic disease of the newborn in sensitized mothers. Approximately 9% of the random RBC donor samples were found to react against K1 (46,47). Anti-K1 is ranked third most clinically significant antibody after ABO and RH(D). HDN induced by anti-K is characterized by immune destruction of K<sup>+</sup> erythroid (47) progenitor cells by macrophages in the fetal liver (48). Frequency of this variant in Middle Easterners was found to be 3.5% which was comparable to Europeans of non-Finnish origin (4.1%) and differ from South Asians (<1%) (49), (50)

Anti-Cr<sup>a</sup> is a rarely encountered antibody against the Cr(a) antigen of the CROMER blood group system. CROM:c.679G>C (rs60822372) variation in exon 6 of CROM gene is responsible for Cr(a-) phenotype which is characterized by the absence of Cr(a) antigen on the RBC membrane. Studies have shown negative crossmatching of individuals carrying the variant in homozygous state and positive while in heterozygous state (51). This variant was observed at a frequency of about 10% in Middle Eastern populations which was found to be comparable to African/African Americans and South Asians (52), (53),(54).

#### *Blood group phenotyping of Qatari subpopulations*

The genomic data of 1005 Qataris comprises 5 major subpopulations namely African (n=70), Arabian (n=193), Bedouin (n=490), Persian (n=170) and South Asian (n=76). Distribution of blood group related variants in different subpopulations was identified and corresponding phenotypes were predicted . In addition, systematic comparisons of allele and phenotype frequencies among the subpopulations were performed.

#### *Comparison and statistical analysis of blood group variants/profiles among Middle Eastern population datasets*

Distinct differences in the minor allele frequencies of blood group alleles between the Middle Easterners and various other global populations were statistically estimated using Fisher's exact test. A total of 26 variants mapping back to 12 blood group systems were found statistically distinct in all the Middle Easterners (Qatar, GME and Iranome) in comparison to global datasets (1000 Genomes Project and gnomAD version?). Summary of these variants along with their p-value is provided in **Supplementary Table 5a**. In addition, differences in the pattern of distribution of these blood group variants were checked among the 5 major Qatari subpopulations. The Arabian subpopulation was found to carry the maximum number of variants whose frequencies were statistically distinct from the overall frequency in the Qatar dataset. Complete details of these variants are tabulated in **Supplementary Table 5b**.

#### *User friendly data access*

*alnasab* (*Alleles and antigens in Arab and Persian populations associated with blood groups*) is a user-friendly online search engine, composed of a comprehensive collection of blood group related variations mined from various population scale datasets of the Greater Middle Eastern region. The resource encompasses a total of 2149 blood group related variants fetched from about 47 blood group genes. The search interface enables the user to query the database based on gene name, variant name (chr-pos:ref>alt), nucleotide change and protein change. Variant information is provided in six different sections namely, (i) Blood group system, (ii) Variant details, (iii) Transcript details, (iv) Variant annotation, (v) Global allele frequencies and (vi) Allele frequencies - Greater Middle East. **Figure 4a and 4b** illustrate the search features and various sections of result display of the resource.

## Discussions

Genomic analysis presented in this study provides the blood group genotype profiles of the Middle Eastern populations utilizing the genome sequencing datasets from Greater Middle East Variome, The Qatar genome and the Iranome. The study reports an array of weak, partial, null and putative novel and rare antigens which were predicted to have potential impact on the functionality. The analyzed and filtered blood group variants along with extensive functional annotations and allele frequencies are provided as a comprehensive online repository - **alnasab**, *Alleles and antigens in Arab and Persian populations associated with blood groups*. The resource is accessible at <https://clingen.igib.res.in/alnasab/>

### *Clinical impact*

An extended screening of blood group antigens between the donors and the recipients other than the major ABO, RH groups and minor DUFFY, KELL and KIDD groups is often triggered only after encountering clinical complications. Frequencies of a total of 26 variants belonging to 12 different blood group systems were found to differ significantly from other global populations. Fetal anaemia and Hemolytic disease of the fetus and newborn (HDFN) are the most serious consequences of transfusion in the majority of pregnancy settings (55). The clinically significant antibodies involved in such cases include Rh, C, E, c and e antigens with greater than 50% risk of mild to severe HDFN (56),(57). Our study reports a weak RHD allele (*RHD\*weak D type 4.0*) with an overall frequency of 0.01% in the Middle eastern population. Often patients carrying this allele get serologically categorized to be transfused with D- RBCs. A recent report from a transfusion work group recommendation explained the necessity of RHD molecular genotyping in expectant mothers which would help categorize RHD alleles that can further allow safe D+ transfusion (42).

### *Literature comparison*

There exists a handful of research studies and reports documenting the blood group profiles of donors across various parts of the Arabian peninsula. Phenotypes of ABO, RH and various other minor blood group systems predicted by standard serological methods were found to match with the genotyping profiling results of the study. (50), (58), (58,59), (60), (61). Js<sup>a</sup> (KEL6) is a low-incidence antigen reported in less than 1% of the general global populations, whereas on other hand, could be prevalent upto 19.5% in African Americans (62). Js(a+b-) phenotype which was not previously reported in serological studies was found in one sample from North East Africa. In compliance with earlier evidence, frequencies of minor blood group phenotypes including Fy(a+b+), K-k+, Lu(a-b+), Jk(a+b+), Do(a+b+), Co(a+) were found comparable.



### *Limitations and future needs*

Owing to the limitations in the available public datasets, our study is mainly limited by the fact that RBC antigenic expressions regulated by large deletions and insertions (especially in RH and MNS blood groups) have not been profiled. In addition, the level of concordance with serology based phenotype predictions to investigate the functional implications of novel and rare variants remains to be explored and validated in future studies.

## **Conclusion**

Middle Easterners represent one of the most genetically diverse populations with increased prevalence of genetic disorders owing to their consanguinity. Autosomal recessive genetic blood disorders including sickle cell disease (SCD), beta thalassemia and hemoglobinopathies are found to be the most common in the Middle Eastern population (63), (18). Increased burden of anemia in women and children is also reported in this population ranging between 22.6-63% in pregnant women, 27-69.6% in women of reproductive age and 23.8-83.5% in children under age of 5 (64). The overall prevalence rates per 1000 population for beta thalassemia and SCD were found as 13.6 and 49.6 respectively (19). Severe forms of such disorders and other chronic illnesses require frequent blood transfusions often leading to dysfunction of multiple organs, if mismatched (65). Extensive population scale characterization of blood group antigen profiles can significantly increase the clinical outcomes of transfusion practices. Numerous national initiatives including Makkah Region Quality Program (MRQP), Central Board of Accreditation for Health Institutions (CBAHI), The Saudi Food and Drug Authority (SFDA), Western Region Transfusion Medicine Group and Saudi Society of Transfusion Medicine (SSTM) have been organized by the Ministry of Health of Saudi Arabia which aims at improving the blood transfusion services in the region (66). Our study showcases the utility of population scale genome sequencing datasets in elucidating the complete blood antigen profiles of the population to guide and improve transfusion practices and outcomes.

## **Funding**

This work was supported by The Council of Scientific and Industrial Research, India (Grant : MLP2001/GenomeApp)


## **Acknowledgements**

VS conceived and designed the project. MR and VS contributed in writing the manuscript. KP designed the database. All authors approved the final manuscript. Authors acknowledge funding from CSIR India. The funders had no role in the preparation of the manuscript or decision to publish. The authors acknowledge the constructive suggestions given by Srashti Jyoti Agrawal and Vishu Gupta.

## **Conflicts of Interest**

None declared.

## **Visual abstract**



## Figures and Tables

**Figure 1.** Schematic representation of the methodology followed for data analysis


**Figure 2.** Overview of the functional classification of blood group related variants in various datasets used in the study

**Figure 3.** Schematic illustration of the distribution of common variants with blood group associated phenotypes along with their corresponding allele frequencies. (A), Heatmap illustrating the similarities and differences in the allele frequencies among various datasets (B), Distribution of blood group related variants in various datasets used in the study (C) Distribution of common alleles among human blood group systems


**Figure 4.** Search query and sections of result display in alnasab. (A) Homepage of the web resource with query search examples. (B) Result display which provides an extensive summary of variant functional annotations in various sections

**Table 1.** Summary of variants with blood group associated phenotypes found commonly in all the Middle Eastern datasets used in the study

**Table 2.** Summary of phenotypes of common blood group variants along with their corresponding zygosity information




**Figure 1.** Schematic representation of the methodology followed for data analysis




**Figure 2.** Overview of the functional classification of blood group related variants in various datasets used in the study

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



**Figure 3.** Schematic illustration of the distribution of common variants with blood group associated phenotypes along with their corresponding allele frequencies. (A), Heatmap illustrating the similarities and differences in the allele frequencies among various datasets (B), Distribution of blood group related variants in various datasets used in the study (C) Distribution of common alleles among human blood group systems



**النسب | alnasab**  
ALLELES AND ANTIGENS IN ARAB & PERSIAN POPULATIONS ASSOCIATED WITH BLOOD GROUPS

Last Updated : 12/01/2022  
 Number of Human blood group systems : 45  
 Number of ISBT approved blood group alleles : 111  
 Number of predicted and curated blood group alleles : 238

### About alnasab

alnasab is a user friendly online search engine, presenting a comprehensive collection of blood group related variations mined from various population scale datasets of the Greater Middle Eastern region. The resource encompasses a total of 2149 blood group related variants fetched from about 47 blood genes. The compiled variants are systematically annotated for their HGVS nomenclature, Global Allele Frequencies and frequencies of various Middle Eastern subpopulations.


ISBT approved Alleles
 Other alleles




Q

**Example Search :**

Gene Name	ABO
Variant Name	chr1-3692014:T>A
Nucleotide Change	c.C19T    c.A976G
Protein Change	p.G813D    p.E128G

**Cite this Resource**

Related references (BGvar) 

Blood group system	
Blood group system :	VEL
Gene Name :	SMIM1
ISBT Blood Group Number :	34

Variant Details	
Chromosome :	1
Position (GRCh37) :	3692014
Reference Allele :	T
Alternate Allele :	A
Variant GRCh37 :	chr1-3692014:T>A
Position GRCh38 :	3775450
Variant GRCh38 :	chr1-3775450:T>A
RefGene Function :	exonic
CytoBand Details :	1p36.32
Exonic Function :	nonsynonymous SNV
Existing Variation ID :	NA

Global Allele Frequencies	
1000 Genomes Project :	NA
ExAC ALL :	NA
ExAC AFR :	NA
ExAC AMR :	NA
ExAC EAS :	NA
ExAC FIN :	NA
ExAC NFE :	NA
ExAC OTH :	NA
ExAC SAS :	NA

Variant Annotation	
SIFT Score :	0.052
SIFT_Prediction :	T
Polyphen2 HVAR Score :	0.015
Polyphen2 HVAR Prediction :	B
LRT Score :	-
LRT Prediction :	-
MutationTaster Score :	1
MutationTaster Prediction :	N
FATHMM Score :	-
FATHMM Prediction :	-
PROVEAN Score :	-0.21
PROVEAN_Prediction :	N
CADD Raw Score :	2.621
CADD Prediction :	20.3
GERP++ RS :	0.146
PhyloP100way Vertebrate :	-0.724
CADD PrePhastCons100way VertebrateRediction :	0
Interpro_Domain :	-

Allele Frequencies - Greater Middle East	
Qatar AF :	0
Qatar AFR :	0
Qatar ARAB :	0
Qatar SAS :	0
Qatar PER :	0
Qatar BED :	0
Iranome Allele Frequency :	0
Iranome Arab AF :	0
Iranome Azeri AF :	0
Iranome Baloch AF :	0

Transcript Details	
RefGene AA change :	SMIM1_NM_001163724.exon3:c.777 A>p.V26E;SMIM1_NM_001288583.exon3:c.777A>p.V26E
Description :	This variant falls on 2 transcripts in 1 gene
Transcripts :	SMIM1_NM_001163724.exon3:c.777 A>p.V26E SMIM1_NM_001288583.exon3:c.777 A>p.V26E
ISBT Approved Transcript :	SMIM1_NM_001163724.exon3:c.777 A>p.V26E
ISBT Approved Transcript Exon :	exon3
Nucleotide Change :	c.777A
Amino Acid Change :	p.V26E
Category :	Predicted Blood Allele
HGVS GRCh37 :	NC_000001.10:g.3692014T>A
HGVS GRCh38 :	NC_000001.11:g.3775450T>A
HGVS_Transcripts :	NM_001163724.1:c.777T>A NR_024432.1:n.325T>A NM_020710.2:c.*5638A>T NM_152492.2:c.*3927T>A

Iranome Lur AF :	0
Iranome Kurd AF :	0
Iranome Persian Gulf Islander AF :	0
Iranome Persian AF :	0
Iranome Turkmen AF :	0
Greater Middle East AF :	0.001184834123
North West Africa Allele Count :	78:00:00
North East Africa Allele Count :	87:00:00
Arabian Peninsula Allele Count :	110:00:00
Israel Allele Count :	6:00:00
Syrian Desert Allele Count :	13:01:00
Turkish Peninsula Allele Count :	83:00:00

**Figure 4.** Search query and sections of result display in alnasab. Homepage of the web resource with query search examples (top). Result display which provides an extensive summary of variant functional annotations in various sections (bottom)

CHR	POS	RSID	REF	ALT	BLOOD GROUP SYSTEM	GENE NAME	CATEGORY	GME_EXOME_AF	QATAR_EXOME_AF	IRANOME_EXOME_AF	EXAC_AF	gnomAD_AF
11	837514	rs139042921	C	T	<b>RAPH</b>	<b>CD151</b>	Combination Mutations	0.00252016129	0.0064	0.000625	0.000109	0.000088
1	207504467	rs60822373	G	C	<b>CROMER</b>	<b>CD55</b>	SNVs	0.004531722054	0.006	0.00125	0	0
1	207760773	rs3737002	C	T	<b>KNOPS</b>	<b>CR1</b>	SNVs	0.2220543807	0	0.24875	0.275008	0.282456
1	207782856	rs17047660	A	G	<b>KNOPS</b>	<b>CR1</b>	SNVs	0.02970795569	0	0.0025	0.021411	0.018156
1	207782889	rs17047661	A	G	<b>KNOPS</b>	<b>CR1</b>	SNVs	0.07552870091	0	0.011875	0.05483	0.046045
1	207782931	rs6691117	A	G	<b>KNOPS</b>	<b>CR1</b>	SNVs	0.3242698892	0	0.33875	0.334107	0.32136
12	14993882	rs28362798	G	A	<b>DOMBROCK</b>	<b>ART4</b>	SNVs	0.008056394763	0.007	0.001875	0	0
12	14993909	rs28362797	C	A	<b>DOMBROCK</b>	<b>ART4</b>	Combination Mutations	0.006042296073	0.0032	0.000625	0.005074	0.003938
1	25611080	rs2301155	C	T	<b>RH</b>	<b>RHD</b>	SNVs	0.007534983854	0.0133	0.00721785	0.000744	0.000814
1	25611101	rs199509194	G	T	<b>RH</b>	<b>RHD</b>	Combination Mutations	0.01885775862	0.0048	0.00197109	0.006653	0.005586
1	25617206	rs113982491	C	T	<b>RH</b>	<b>RHD</b>	SNVs	0.003715498938	0.0059	0.00265604	0.006654	0.005781
1	25617251	rs17418085	A	C	<b>RH</b>	<b>RHD</b>	Combination Mutations	0.006417112299	0	0.00268097	0.006627	0.005444
1	25627552	rs1053355	C	G	<b>RH</b>	<b>RHD</b>	SNVs	0.01397849462	0	0.00534045	0.00509	0.004695
1	25628043	rs1053356	T	G	<b>RH</b>	<b>RHD</b>	SNVs	0.02355460385	0.0171	0.00604027	0.012114	0.010346
1	25628050	rs148014996	C	T	<b>RH</b>	<b>RHD</b>	Combination Mutations	0.003198294243	0.0064	0.00134048	0.004099	0.003447
1	25628073	rs1053359	G	C	<b>RH</b>	<b>RHD</b>	SNVs	0.003735325507	0.0047	0.00201072	0	0
1	25628120	rs1053362	C	T	<b>RH</b>	<b>RHD</b>	SNVs	0.004823151125	0.0021	0.0026738	0.001182	0.001057
1	25629818	rs141833592	T	G	<b>RH</b>	<b>RHD</b>	SNVs	0.002212389381	0.0065	0.00134953	0.00452	0.00333
1	25629830	rs150606530	G	A	<b>RH</b>	<b>RHD</b>	SNVs	0.01161504425	0.0041	0.00268456	0.00429	0.003532
1	25633104	rs146292192	G	A	<b>RH</b>	<b>RHD</b>	SNVs	0.004237288136	0.0021	0.00268097	0.000572	0.000591
1	25633172	rs138235491	T	C	<b>RH</b>	<b>RHD</b>	SNVs	0.004777070064	0.0021	0.00266312	0.000609	0.000639
1	25648421	rs150059028	G	A	<b>RH</b>	<b>RHD</b>	SNVs	0.008269018743	0.0158	0.00879567	0.004184	0.004362

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

1	25712269	rs116261244	C	A	<b>RH</b>	<b>RHCE</b>	SNVs	0.001007049345	0	0.00125	0.0035	0.002871
1	25715490	rs1132765	T	C	<b>RH</b>	<b>RHCE</b>	SNVs	0	0.0016	0.001875	0.000512	0.000466
1	25717308	rs1053361	G	C	<b>RH</b>	<b>RHCE</b>	SNVs	0.06344410876	0.0368	0.008125	0.022719	0
1	25717329	rs144163296	T	C	<b>RH</b>	<b>RHCE</b>	SNVs	0.004028197382	0.0035	0.001875	0.001343	0.000951
1	25717365	rs609320	C	G	<b>RH</b>	<b>RHCE</b>	SNVs	0.1299093656	0.1716	0.161875	0.162186	0.169006
1	25729212	rs1053345	T	A	<b>RH</b>	<b>RHCE</b>	SNVs	0.0005035246727	0.0006	0.006875	0.001903	0.001786
1	25735255	rs57992529	G	C	<b>RH</b>	<b>RHCE</b>	SNVs	0.005415162455	0.0022	0.000877193	0	0
1	25747156	rs138268848	T	C	<b>RH</b>	<b>RHCE</b>	SNVs	0.008503401361	0.0041	0.00875	0.01081	0.010245
1	25747173	rs142971926	G	A	<b>RH</b>	<b>RHCE</b>	SNVs	0.009029345372	0.0035	0.000625	0	0
15	74703929	rs741761	T	C	<b>JMH</b>	<b>SEMA7A</b>	Combination Mutations	0.4310171198	0.4922	0.431875	0	0
18	43310313	rs113578396	G	A	<b>KIDD</b>	<b>SLC14A1</b>	Combination Mutations	0.027693857	0.026	0.009375	0.006567	0
18	43310415	rs2298720	G	A	<b>KIDD</b>	<b>SLC14A1</b>	Combination Mutations	0.1218529708	0.0796	0.1375	0.147459	0.151956
18	43311054	rs113029149	G	A	<b>KIDD</b>	<b>SLC14A1</b>	Combination Mutations	0.02923387097	0.0299	0.009375	0.008122	0.00692
18	43311131	rs28994287	G	A	<b>KIDD</b>	<b>SLC14A1</b>	Combination Mutations	0.02947154472	0	0.009375	0.007885	0.006644
18	43316461	rs9948825	T	C	<b>KIDD</b>	<b>SLC14A1</b>	SNVs	0.001510574018	0	0.000625	0.001507	0.001153
18	43316538	rs2298718	A	G	<b>KIDD</b>	<b>SLC14A1</b>	Combination Mutations	0.5730110775	0.4562	0.590625	0.36427	0.361846
18	43319274	rs17675299	G	A	<b>KIDD</b>	<b>SLC14A1</b>	SNVs	0.03675730111	0	0.053125	0	0
18	43319519	rs1058396	G	A	<b>KIDD</b>	<b>SLC14A1</b>	SNVs	0.4058408862	0.3323	0.439375	0.46954	0.471467
18	43328350	rs565898944	C	T	<b>KIDD</b>	<b>SLC14A1</b>	SNVs	0	0	0.0025	0.000651	0.00066
18	43329841	rs28898897	T	C	<b>KIDD</b>	<b>SLC14A1</b>	Combination Mutations	0.01762336354	0.0264	0.010625	0.004547	0.004667
19	12996740	rs2072597	A	G	<b>KLF1</b>	<b>KLF1</b>	Combination Mutations	0.2962771458	0.2835	0.325448	0.43921	0.368599
19	45315445	rs28399653	G	A	<b>LUTHERAN</b>	<b>BCAM</b>	Combination Mutations	0.01209677419	0	0.0131579	0	0

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

19	45315539	rs3745159	G	A	<b>LUTHERAN</b>	<b>BCAM</b>	Combinat ion Mutation s	0.02620 967742	0.0278	0.02875	0.0234 69	0.0215 2
19	45316704	rs28399656	T	A	<b>LUTHERAN</b>	<b>BCAM</b>	SNVs	0.02769 3857	0.035	0.020025	0.0095 57	0.0094 85
19	45316804	rs3810141	C	T	<b>LUTHERAN</b>	<b>BCAM</b>	Combinat ion Mutation s	0.07703 927492	0.0682	0.1025	0.0879 96	0.0862 07
19	45316807	rs3810140	C	T	<b>LUTHERAN</b>	<b>BCAM</b>	Combinat ion Mutation s	0.07552 870091	0.0661	0.1025	0.0856 24	0.0841 9
19	45322316	rs117737673	C	T	<b>LUTHERAN</b>	<b>BCAM</b>	Combinat ion Mutation s	0.01560 926485	0.0095	0.02375	0.0222 28	0.0210 63
19	45322744	rs1135062	A	G	<b>LUTHERAN</b>	<b>BCAM</b>	Combinat ion Mutation s	0.330312 1853	0.2964	0.275	0.2753 29	0.2725 9
19	45322891	rs28399658	C	T	<b>LUTHERAN</b>	<b>BCAM</b>	Combinat ion Mutation s	0.03776 435045	0.0643	0.0575	0.0315 62	0.0296 53
19	45322962	rs28399659	A	T	<b>LUTHERAN</b>	<b>BCAM</b>	Combinat ion Mutation s	0.03850 050659	0.066	0.055625	0.0348 72	0.0297 57
19	49254504	rs2071699	G	A	<b>H</b>	<b>FUT1</b>	SNVs	0.041792 54783	0.0462	0.065625	0.0578 46	0.0590 25
2	220080845	rs60322991	C	T	<b>LANGEREIS</b>	<b>ABCB6</b>	SNVs	0.008611 95542	0.0201	0.00125	0.01911	0.0109 4
2	220081416	rs57467915	G	A	<b>LANGEREIS</b>	<b>ABCB6</b>	SNVs	0.00405 2684904	0.0006	0.000625	0.0189 5	0.0087 83
22	43088971	rs9623659	C	T	<b>PIPK</b>	<b>A4GALT</b>	Combinat ion Mutation s	0.41683 46774	0.4468	0.340625	0.3523 91	0.3503 11
22	43089849	rs11541159	T	C	<b>PIPK</b>	<b>A4GALT</b>	SNVs	0.41809 909	0.4485	0.341875	0.3867 2	0.3491 5
3	160804167	rs2231257	C	T	<b>GLOB</b>	<b>B3GALNT 1</b>	SNVs	0.04833 836858	0.0711	0.06	0.0456 55	0.0448 4
4	144920596	rs7683365	G	A	<b>MNS</b>	<b>GYPB</b>	Combinat ion Mutation s	0.33383 6858	0	0.360625	0.3456 92	0
4	89013496	rs34783571	C	T	<b>JUNIOR</b>	<b>ABCG2</b>	SNVs	0.00860 3238866	0.0065	0.0175	0.0055 56	0.0052 04
4	89052323	rs2231142	G	T	<b>JUNIOR</b>	<b>ABCG2</b>	Combinat ion Mutation s	0.05186 304129	0.0517	0.07625	0.11801 7	0.1246 55
4	89061114	rs2231137	C	T	<b>JUNIOR</b>	<b>ABCG2</b>	Combinat ion Mutation s	0.106243 7059	0	0.11125	0.1075 81	0.11418 9
6	10586727	rs56106312	G	A	<b>I</b>	<b>GCNT2</b>	SNVs	0.002517 623364	0.0043	0.0025	0	0
6	49580247	rs16879498	C	T	<b>RHAG</b>	<b>RHAG</b>	Combinat ion Mutation s	0.05945 121951	0	0.036875	0.0434 54	0.0420 61



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

7	142640004	rs8176039	T	C	<b>KELL</b>	<b>KEL</b>	Combinat ion Mutations	0.02416 918429	0.0328	0.0075	0.0209 58	0.0173 51
7	142640113	rs8176038	A	G	<b>KELL</b>	<b>KEL</b>	SNVs	0.011077 5428	0	0.001875	0.0083 55	0.0067 38
7	142640596	rs8176036	T	G	<b>KELL</b>	<b>KEL</b>	Combinat ion Mutations	0.03373 615307	0.0274	0.02125	0.0528 12	0.0504 72
7	142640916	rs8176034	G	T	<b>KELL</b>	<b>KEL</b>	SNVs	0.02668 680765	0	0.003125	0	0
7	142641752	rs190890637	G	A	<b>KELL</b>	<b>KEL</b>	SNVs	0.001510 574018	0	0.0025	0.0002 16	0.0002 11
7	142651354	rs8176059	G	A	<b>KELL</b>	<b>KEL</b>	Combinat ion Mutations	0.00352 4672709	0.0023	0.0025	0.0071 8	0.0069 76
7	142655008	rs8176058	G	A	<b>KELL</b>	<b>KEL</b>	Combinat ion Mutations	0.04481 369587	0.0478	0.03125	0.0274 38	0.0268 98
7	30951658	rs28362692	C	T		<b>AQP1</b>	SNVs	0.00805 6394763	0.004	0.005625	0.0264 68	0
7	30951664	rs377506522	A	G		<b>AQP1</b>	SNVs	0.00201 4098691	0.0011	0.004375	0.0001 91	0.0001 99
9	136029645	rs35898523	G	T	<b>FORS</b>	<b>GBGT1</b>	SNVs	0.09182 643794	0.1328	0.1	0	0
9	136037742	rs2073924	G	A	<b>FORS</b>	<b>GBGT1</b>	SNVs	0.222557 9053	0.2193	0.232704	0.27771 1	0.11379 3
9	136136773	rs8176696	C	T	<b>ABO</b>	<b>ABO</b>	SNVs	0.01359 516616	0	0.009375	0	0
1	43296572	rs33954154	C	T	<b>SCIANNA</b>	<b>ERMAP</b>	Combinat ion Mutations	0.00856 8548387	0.0037	0.000625	0.0081 39	0.0063 98

**Table 1.** Summary of variants with blood group associated phenotypes found commonly in all the Middle Eastern datasets used in the study

BLOOD GROUP	CHR	POS	RSID	REF	ALT	GENE NAME	PHENOTYPE DESCRIPTION	VARIANT TYPE	QATAR HOM COUNT	QATAR HET COUNT	IRANOME HOM COUNT	IRANOME HET COUNT	GME HOM COUNT	GME HET COUNT	HET
<b>RAPH</b>	11	837514	rs139042921	C	T	<b>CD151</b>	<i>RAPH</i> -1 or <i>MER2</i> -	Combination mutation			0	2	0	5	
<b>CROMER</b>	1	207504467	rs60822373	G	C	<b>CD55</b>	<i>Cr(a-)</i> - Altered phenotype	SNVs	1	9	0	2	1	7	
<b>KNOPS</b>	1	207760773	rs3737002	C	T	<b>CR1</b>	<i>Yk(a-)</i>	SNVs	4	27	53	292	74	293	
	1	207782856	rs17047660	A	G	<b>CR1</b>	<i>McC(b+)</i>	SNVs	1	3	0	4	7	45	
	1	207782889	rs17047661	A	G	<b>CR1</b>	<i>Vil+</i>	SNVs	4	10	1	17	17	116	

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

	1	207 782 931	rs66 9111 7	A	G	<b>CR1</b>	KCAM-	SNVs	15	36	107	328	124	396
<b>DOMBROCK</b>	12	149 938 82	rs28 362 798	G	A	<b>ART4</b>	DO:-5 or Jo(a-)	Combination mutation	0	14	0	3	1	14
	12	149 939 09	rs28 362 797	C	A	<b>ART4</b>	DO:-4 or Hy-. Combination mutation with rs11276	SNVs	0	6	0	1	0	12
<b>RH</b>	1	256 110 80	rs23 0115 5	C	T	<b>RHD</b>	Weak expression - Combination with 25648439 pos	Combination mutation	1	23	0	11	0	14
	1	256 1110 1	rs19 950 9194	G	T	<b>RHD</b>		Combination mutation	2	5	1	1	1	33
	1	256 172 06	rs113 982 491	C	T	<b>RHD</b>	Del or weak D	Combination mutation	3	5	1	2	2	3
	1	256 172 51	rs17 418 085	A	C	<b>RHD</b>		Combination mutation	2	8	1	2	4	4
	1	256 275 52	rs10 533 55	C	G	<b>RHD</b>	RHD*01W.40 - Weak expression	SNVs	0	3	2	4	8	10
	1	256 280 43	rs10 533 56	T	G	<b>RHD</b>	RHD*08.01	SNVs	6	20	2	5	12	20
	1	256 280 50	rs14 801 499 6	C	T	<b>RHD</b>		Combination mutation	1	10	1	0	2	2
	1	256 280 73	rs10 533 59	G	C	<b>RHD</b>	RHD*05.04/RH D*05.05	SNVs	1	6	0	3	1	5
	1	256 281 20	rs10 533 62	C	T	<b>RHD</b>		Combination mutation	0	4	1	2	1	7
	1	256 298 18	rs141 833 592	T	G	<b>RHD</b>	RHD*01N.18 (D negative)	SNVs	1	10	1	0	2	1
	1	256 298 30	rs15 060 653 0	G	A	<b>RHD</b>		Combination mutation	2	3	1	2	7	7
	1	256 331 04	rs14 629 2192	G	A	<b>RHD</b>		Combination mutation	0	4	1	2	2	4
	1	256 331 72	rs13 823 5491	T	C	<b>RHD</b>		Combination mutation	0	4	1	2	2	5
	1	256 484 21	rs15 005 902 8	G	A	<b>RHD</b>	RHD*01W.45 Weak expression	SNVs	10	7	1	11	3	9
1	257 122 69	rs11 6261 244	C	A	<b>RHCE</b>		Combination	0	3	0	2	0	2	

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

									mutatio n								
	1	257 154 90	rs113 276 5	T	C	<b>RHCE</b>			Combin ation mutatio n	0	3	0	3	0	0		
	1	257 173 08	rs10 533 61	G	C	<b>RHCE</b>	<i>c+ partial e+ partial/ C+e+</i>	SNVs	5	64	0	13	17	92			
	1	257 173 29	rs14 4163 296	T	C	<b>RHCE</b>			Combin ation mutatio n	0	7	0	3	0	8		
	1	257 173 65	rs60 932 0	C	G	<b>RHCE</b>			Combin ation mutatio n	28	289	23	213	26	206		
	1	257 292 12	rs10 533 45	T	A	<b>RHCE</b>			Combin ation mutatio n	0	1	1	9	0	1		
	1	257 352 55	rs57 992 529	G	C	<b>RHCE</b>	<i>e+ weak partial</i>	SNVs	1	1	0	1	4	1			
	1	257 471 56	rs13 826 884 8	T	C	<b>RHCE</b>	<i>RH:8 (Cw+) or partial C+ partial e+ RH:8 (Cw+) RH:-51(MAR-)</i>	SNVs	0	7	1	12	4	7			
	1	257 471 73	rs14 2971 926	G	A	<b>RHCE</b>				0	7	0	1	0	16		
	<b>JMH</b>	15	747 039 29	rs74 1761	T	C	<b>SEMA7 A</b>	<i>JMH: -7 or JMHN- Combination with rs140707085 and rs140128092</i>	Combin ation mutatio n	214	397	167	357	207	442		
		18	433 103 13	rs113 578 396	G	A	<b>SLC14A 1</b>	<i>Jk(a+W) ; Jk(a+W) - Combination with rs113029149 ; JK:-3 or Jk(a-b-) - Combination with rs113029149, rs28994287 and rs2298718</i>	SNVs	2	48	0	15	6	43		
	<b>KIDD</b>	18	433 104 15	rs22 987 20	G	A	<b>SLC14A 1</b>	<i>Jk(a+W); Jk(b+W); JK:-3 or Jk(a-b-) - Combination mutation</i>	SNVs	16	128	19	182	31	180		
		18	433 110 54	rs113 0291 49	G	A	<b>SLC14A 1</b>	<i>Jk(a+W); Jk(a+W) - Combination with rs113578396; Jk(a-b-) - Combination with rs113578396, rs28994287 and rs2298718</i>	SNVs	2	56	0	15	5	48		
		18	433 1113 1	rs28 994 287	G	A	<b>SLC14A 1</b>	<i>JK:-3 or Jk(a-b-) - Combination</i>	ation	0	4	0	15	7	44		

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

							with rs113578396, rs113029149 and rs2298718	mutatio n							
	18	433 164 61	rs99 488 25	T	C	<b>SLC14A 1</b>	Jk(a+W)	SNVs	0	1	0	1	0	3	
	18	433 165 38	rs22 9871 8	A	G	<b>SLC14A 1</b>	Jk(a+W); Jk(b+W) ; JK:-3 or Jk(a-b-) - Combination mutation	SNVs	229	459	283	379	369	400	
	18	433 192 74	rs17 675 299	G	A	<b>SLC14A 1</b>	JK:-3 or Jk(a-b-) - Combination with rs113578396, rs113029149 and rs2298718	SNVs	0	3	2	81	9	55	
	18	433 1951 9	rs10 583 96	G	A	<b>SLC14A 1</b>		SNVs	123	422	166	371	192	422	
	18	433 283 50	rs56 589 894 4	C	T	<b>SLC14A 1</b>	JK:-3 or Jk(a-b-); JK:-3 or Jk(a-b-). Both JK*01 and JK*02	SNVs	0	1	0	4	0	0	
	18	433 298 41	rs28 898 897	T	C	<b>SLC14A 1</b>	Jk(b+W) - Combination mutation with rs774982134	Combina tion mutatio n	1	51	2	13	5	25	
<b>KLF1</b>	19	129 967 40	rs20 725 97	A	G	<b>KLF1</b>	*Obsolete* Normal phenotype; In(Lu) Combination mutation;	Obsolet e mutatio n	83	346	86	337	125	323	
<b>LUTHER AN</b>	19	453 154 45	rs28 399 653	G	A	<b>BCAM</b>	LU:1 or Lu(a+) ; LU:-16 Combination mutation; LU:1,19 Combination mutation	SNVs	0	1	1	19	2	20	
	19	453 155 39	rs37 4515 9	G	A	<b>BCAM</b>	LU:-27, LUYA- Combination mutation	Combina tion mutatio n	1	53	2	42	3	46	
	19	453 167 04	rs28 399 656	T	A	<b>BCAM</b>	LU:-8,14	SNVs	2	65	0	32	4	47	
	19	453 168 04	rs38 1014 1	C	T	<b>BCAM</b>		SNVs	10	114	9	146	15	123	
	19	453 168 07	rs38 1014 0	C	T	<b>BCAM</b>	LU:-24, LUGA- Combination mutation	Combina tion mutatio n	9	112	9	146	15	120	
	19	453 223 16	rs117 737 673	C	T	<b>BCAM</b>	LU:-13 Combination mutation ; Lu(b+w) - Combination mutation	Combina tion mutatio n	1	17	0	38	4	23	
	19	453 227 44	rs113 506 2	A	G	<b>BCAM</b>	LU:1,19 Combination mutation; LU:-18,19 or	SNVs	94	390	67	306	130	396	

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

								<i>Au(a-b+); LU:-18,19,-8,14 - Combination mutation</i>							
	19	453 228 91	rs28 399 658	C	T	<b>BCAM</b>		<i>Lu(b+w); LU:-13 - Combination mutations</i>	Combination mutation	5	116	1	90	5	65
	19	453 229 62	rs28 399 659	A	T	<b>BCAM</b>		<i>Lu(b+w); LU:-13 - Combination mutations</i>	Combination mutation	5	114	1	87	8	60
<b>H</b>	19	492 545 04	rs20 7169 9	G	A	<b>FUT1</b>	<i>H+</i>		SNVs	3	86	3	99	5	73
<b>LANGER EIS</b>	2	220 080 845	rs60 322 991	C	T	<b>ABCB6</b>	<i>Lan weak</i>		SNVs	0	33	0	2	1	15
	2	220 081 416	rs57 467 915	G	A	<b>ABCB6</b>	<i>Lan weak</i>		SNVs	0	1	0	1	0	8
<b>P1PK</b>	22	430 889 71	rs96 236 59	C	T	<b>A4GAL T</b>	<i>p - Combination mutation</i>		Combination mutation	208	466	89	367	198	431
	22	430 898 49	rs11 5411 59	T	C	<b>A4GAL T</b>	<i>P1+/-, Pk+</i>		SNVs	211	466	90	367	193	441
<b>GLOB</b>	3	160 804 167	rs22 3125 7	C	T	<b>B3GAL NT1</b>	<i>GLOB:1 (P+)</i>		SNVs	6	131	5	86	6	84
<b>MNS</b>	4	144 920 596	rs76 833 65	G	A	<b>GYPB</b>	<i>MNS:3 or S+</i>		SNVs	12	43	111	355	128	407
<b>JUNIOR</b>	4	890 134 96	rs34 783 571	C	T	<b>ABCG2</b>	<i>Jr(a+w)</i>		SNVs	0	13	1	26	1	15
	4	890 523 23	rs22 3114 2	G	T	<b>ABCG2</b>	<i>Jr(a+w) ; Jr(a-) - Combination mutation</i>		Combination mutation	3	98	5	112	9	85
	4	890 6111 4	rs22 3113 7	C	T	<b>ABCG2</b>	<i>Jr(a-) - Combination mutation;</i>		Combination mutation	0	16	7	164	19	173
<b>I</b>	6	105 867 27	rs56 1063 12	G	A	<b>GCNT2</b>	<i>I+W</i>		Combination mutation	1	6	0	4	0	5
<b>RHAG</b>	6	495 802 47	rs16 879 498	C	T	<b>RHAG</b>	<i>Rhnull Combination mutation</i>		Combination mutation	0	7	2	55	12	93
<b>KELL</b>	7	142 640 004	rs81 760 39	T	C	<b>KEL</b>	<i>Kmod Combination mutation</i>		Combination mutation	5	56	0	12	3	42
	7	142 640 113	rs81 760 38	A	G	<b>KEL</b>	<i>KEL:6,-7 or Js(a+b-)</i>		SNVs	0	3	0	3	1	20
	7	142 640 596	rs81 760 36	T	G	<b>KEL</b>	<i>Kmod Combination mutation</i>		Combination mutation	1	53	1	32	3	61

	7	142 640 916	rs81 760 34	G	T	<b>KEL</b>	KEL:2 or k+/Ko	SNVs	0	3	0	5	5	43
	7	142 641 752	rs19 089 063 7	G	A	<b>KEL</b>	KEL:-36 or KETI-	SNVs	0	1	0	4	0	3
	7	142 651 354	rs81 760 59	G	A	<b>KEL</b>	KEL:1weak,3 or K+w, Kp(a+) - Combined with rs8176058; KEL:3,-4,-21 or Kp(a+b-c-) ; KO - Combined with rs1268359042; Kmod - Combined with rs777011308	SNVs	0	4	0	4	0	7
	7	142 655 008	rs81 760 58	G	A	<b>KEL</b>	KEL:1,-2 or K+k-; KEL:1weak,3 or K+w, Kp(a+) - Combined with rs8176059; KO - Combination mutation; Kmod - Combination mutation	SNVs	4	88	1	48	4	81
<b>COLTON</b>	7	309 516 58	rs28 362 692	C	T	<b>AQP1</b>	CO:2 or Co(b+)	SNVs	0	8	0	9	0	16
	7	309 516 64	rs37 750 652 2	A	G	<b>AQP1</b>	CO:-1,-2,3,-4	SNVs	0	2	1	5	0	4
<b>FORS</b>	9	136 029 645	rs35 898 523	G	T	<b>GBGT1</b>	FORS:-1 (FORS-)	SNVs	22	223	7	146	22	138
	9	136 037 742	rs20 739 24	G	A	<b>GBGT1</b>	FORS:-1 (FORS-)	SNVs	44	341	53	264	61	320
<b>ABO</b>	9	1361 367 73	rs81 766 96	C	T	<b>ABO</b>		Combination mutation	0	2	0	15	0	27
<b>SCIANN A</b>	1	432 965 72	rs33 9541 54	C	T	<b>ERMAP</b>	SC:-9 or SCAC- - Combination mutation	SNVs	0	7	0	1	2	13

**Table 2.** Summary of phenotypes of common blood group variants along with their corresponding zygosity information

## Supplementary Datasets

**Supplementary Table 1.** Brief tabulation of number of variants found associated with human blood group genes in the datasets used in the study.

[Summary of blood group variants in study datasets](#)

**Supplementary Table 2.** Tabulation of blood group alleles predicted to match ISBT approved phenotypes and reference genome nomenclature in Middle Eastern population datasets

[Predicted phenotypes of blood group systems in Middle Eastern population](#)

**Supplementary Table 3.** Summary of distribution of novel and rare blood group variants in GME datasets predicted to be deleterious by at least three or more computational tools.

[Tabulation of potentially novel and deleterious blood group variants in GME datasets](#)

**Supplementary Table 4.** Comprehensive tabulation of weak/partial or null allele variants found in Middle Eastern populations along with their zygosity information.

[Summary of weak or partial antigens identified in the study dataset](#)


**Supplementary Table 5a.** Summary of statistically distinct blood group variants identified between the Middle East and global population datasets

[Distinct blood group variants between the Middle East and global populations](#)

**Supplementary Table 5b.** Summary of statistically distinct blood group variants observed among the Qatari subpopulations

[Distinct blood group variants among Qatari subpopulations](#)

**Supplementary Figure 1.** Distribution of statistically distinct blood group variants in various Middle Eastern datasets and among Qatari subpopulations



**Supplementary Figure 1.** Distribution of statistically distinct blood group variants. (A) Summary of blood group variants which were found statistically distinct in various Middle Eastern datasets in comparison to global population data. (B) Distribution of statistically distinct blood group variants among the major Qatari subpopulations in comparison to the overall Qatar frequencies.

## References

1. Seltsam, A. and Doescher, A. (2009) Sequence-Based Typing of Human Blood Groups. *Sequence-Based Typing of Human Blood Groups. Transfusion Medicine and Hemotherapy* (2009), 36, 204–212.
2. Reid, M.E. (2007) Overview of molecular methods in immunohematology. *Transfusion*, 47, 10S–6S.
3. Liu, Z., Liu, M., Mercado, T., Illoh, O. and Davey, R. (2014) Extended blood group molecular typing and next-generation sequencing. *Transfus. Med. Rev.*, 28, 177–186.
4. Hershkovitz, I., Weber, G.W., Quam, R., Duval, M., Grün, R., Kinsley, L., Ayalon, A., Bar-Matthews, M., Valladas, H., Mercier, N., et al. (2018) The earliest modern humans outside Africa. *Science*, 359, 456–459.
5. Groucutt, H.S., Grün, R., Zalmout, I.A.S., Drake, N.A., Armitage, S.J., Candy, I., Clark-Wilson, R., Louys, J., Breeze, P.S., Duval, M., et al. (2018) Homo sapiens in Arabia by 85,000 years ago. *Nat Ecol Evol*, 2, 800–809.
6. Hellenthal, G., Busby, G.B.J., Band, G., Wilson, J.F., Capelli, C., Falush, D. and Myers, S. (2014) A genetic atlas of human admixture history. *Science*, 343, 747–751.
7. Arauna, L.R., Mendoza-Revilla, J., Mas-Sandoval, A., Izaabel, H., Bekada, A., Benhamamouch, S., Fadhlouzi-Zid, K., Zalloua, P., Hellenthal, G. and Comas, D. (2017) Recent Historical Migrations Have Shaped the Gene Pool of Arabs and Berbers in North Africa. *Mol. Biol. Evol.*, 34, 318–329.
8. Banihashemi, K. (2009) Iranian human genome project: Overview of a research process among Iranian ethnicities. *Indian J. Hum. Genet.*, 15, 88–92.
9. Fattahi, Z., Beheshtian, M., Mohseni, M., Poustchi, H., Sellars, E., Nezhadi, S.H., Amini, A., Arzhang, S., Jalalvand, K., Jamali, P., et al. (2019) Iranome: A catalog of genomic variations in the Iranian population. *Hum. Mutat.*, 40, 1968–1984.
10. Fakhro, K.A., Staudt, M.R., Ramstetter, M.D., Robay, A., Malek, J.A., Badii, R., Al-Marri, A.A.-N., Khalil, C.A., Al-Shakaki, A., Chidiac, O., et al. (2016) The Qatar genome: a population-specific tool for precision medicine in the Middle East. *Human Genome Variation*, 3, 1–7.
11. Mbarek, H., Gandhi, G.D., Selvaraj, S., Al-Muftah, W., Badji, R., Al-Sarraj, Y., Saad, C., Darwish, D., Alvi, M., Fadl, T., et al. (2021) Qatar Genome: Insights on Genomics from the Middle East. *medRxiv*, 2021.09.19.21263548.
12. Razali, R.M., Rodriguez-Flores, J., Ghorbani, M., Naeem, H., Aamer, W., Aliyev, E., Jubran, A., Clark, A.G., Fakhro, K.A. and Mokrab, Y. (2021) Thousands of Qatari genomes inform human migration history and improve imputation of Arab haplotypes. *Nat. Commun.*, 12, 1–16.
13. Bashwari, L.A., Al-Mulhim, A.A., Ahmad, M.S. and Ahmed, M.A. (2001) Frequency of ABO blood groups in the Eastern region of Saudi Arabia. *Saudi Med. J.*, 22, 1008–1012.
14. Owaidah, A.Y., Naffaa, N.M., Alumran, A. and Alzahrani, F. (2020) Phenotype Frequencies of Major Blood Group Systems (Rh, Kell, Kidd, Duffy, MNS, P, Lewis, and Lutheran) Among Blood Donors in the Eastern Region of Saudi Arabia. *J. Blood Med.*, 11, 59–65.
15. Sarhan, M.A., Saleh, K.A. and Bin-Dajem, S.M. (2009) Distribution of ABO blood groups and rhesus factor in Southwest Saudi Arabia. *Saudi Med. J.*, 30, 116–119.
16. Ameen, R., Al Shemmari, S., Harris, S., Teramura, G. and Delaney, M. (2020) Classification of major and minor blood group antigens in the Kuwaiti Arab population. *Transfus. Apher. Sci.*, 59, 102748.
17. Yip, S.P., Choi, P.S., Lee, S.Y., Leung, K.H., El-Zawahri, M.M. and Luqmani, Y.A. (2006) ABO blood group in Kuwaitis: detailed allele frequency distribution and identification of novel



- alleles. *Transfusion* , **46**, 773–779.
18. Natarajan, J. and Joseph, M.A. (2021) Premarital screening for genetic blood disorders — an integrated review on the knowledge and attitudes of Middle Eastern university students. Premarital screening for genetic blood disorders — an integrated review on the knowledge and attitudes of Middle Eastern university students. *Middle East Fertility Society Journal* (2021) , 26.
  19. Alsaeed, E.S., Farhat, G.N., Assiri, A.M., Memish, Z., Ahmed, E.M., Saeedi, M.Y., Al-Dossary, M.F. and Bashawri, H. (2017) Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011–2015. Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011–2015. *Journal of Epidemiology and Global Health* (2017) , 7, S41.
  20. Bailey, M., Gibbs, M., Dani, N., Mendell, A. and Thompson, M. (2019) Burden of Illness of Sickle Cell Disease in Countries of the Middle East: A Systematic Literature Review. Burden of Illness of Sickle Cell Disease in Countries of the Middle East: A Systematic Literature Review. *Blood* (2019) , 134, 5867–5867.
  21. Scott, E.M., Halees, A., Itan, Y., Spencer, E.G., He, Y., Azab, M.A., Gabriel, S.B., Belkadi, A., Boisson, B., Abel, L., et al. (2016) Characterization of Greater Middle Eastern genetic variation for enhanced disease gene discovery. *Nat. Genet.*, **48**, 1071–1076.
  22. MacArthur, J.A.L., Morales, J., Tully, R.E., Astashyn, A., Gil, L., Bruford, E.A., Larsson, P., Flicek, P., Dalgleish, R., Maglott, D.R., et al. (2014) Locus Reference Genomic: reference sequences for the reporting of clinically relevant sequence variants. *Nucleic Acids Res.*, **42**, D873–8.
  23. Rophina, M., Teh, L.K., Sivasubbu, S., Scaria, V. and Salleh, M.Z. (2021) Genomic map of blood group alleles in Malaysian indigenous Orang Asli population from whole genome sequences. *medRxiv*, 2021.12.04.21267232.
  24. Storry, J.R., Clausen, F.B., Castilho, L., Chen, Q., Daniels, G., Denomme, G., Flegel, W.A., Gassner, C., de Haas, M., Hyland, C., et al. (2019) International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology: Report of the Dubai, Copenhagen and Toronto meetings. *Vox Sang.*, **114**, 95–102.
  25. Patnaik, S.K., Helmsberg, W. and Blumenfeld, O.O. (2014) BGMUT Database of Allelic Variants of Genes Encoding Human Blood Group Antigens. *Transfus. Med. Hemother.*, **41**, 346–351.
  26. Möller, M., Jöud, M., Storry, J.R. and Olsson, M.L. (2016) ErythroGene: a database for in-depth analysis of the extensive variation in 36 blood group systems in the 1000 Genomes Project. *Blood Adv*, **1**, 240–249.
  27. Wagner, F.F. and Flegel, W.A. (2014) The Rhesus Site. *Transfus. Med. Hemother.*, **41**, 357–363.
  28. Lane, W.J., Vege, S., Mah, H.H., Lomas-Francis, C., Aguad, M., Smeland-Wagman, R., Koch, C., Killian, J.M., Gardner, C.L., De Castro, M., et al. (2019) Automated typing of red blood cell and platelet antigens from whole exome sequences. *Transfusion* , **59**, 3253–3263.
  29. Lane, W.J., Westhoff, C.M., Gleadall, N.S., Aguad, M., Smeland-Wagman, R., Vege, S., Simmons, D.P., Mah, H.H., Lebo, M.S., Walter, K., et al. (2018) Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. *Lancet Haematol*, **5**, e241–e251.
  30. Rophina, M., Pandhare, K., Jadhao, S., Nagaraj, S.H. and Scaria, V. (2021) BGvar: A comprehensive resource for blood group immunogenetics. *Transfus. Med.*
  31. Ng, P.C. and Henikoff, S. (2003) SIFT: Predicting amino acid changes that affect protein

- function. *Nucleic Acids Res.*, **31**, 3812–3814.
32. Adzhubei, I., Jordan, D.M. and Sunyaev, S.R. (2013) Predicting functional effect of human missense mutations using PolyPhen-2. *Curr. Protoc. Hum. Genet.*, **Chapter 7**, Unit7.20.
  33. Gnad, F., Baucom, A., Mukhyala, K., Manning, G. and Zhang, Z. (2013) Assessment of computational methods for predicting the effects of missense mutations in human cancers. *BMC Genomics*, **14 Suppl 3**, S7.
  34. Shihab, H.A., Gough, J., Cooper, D.N., Stenson, P.D., Barker, G.L.A., Edwards, K.J., Day, I.N.M. and Gaunt, T.R. (2013) Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. *Hum. Mutat.*, **34**, 57–65.
  35. Choi, Y. and Chan, A.P. (2015) PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. *Bioinformatics*, **31**, 2745–2747.
  36. Rentzsch, P., Witten, D., Cooper, G.M., Shendure, J. and Kircher, M. (2019) CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.*, **47**, D886–D894.
  37. Davydov, E.V., Goode, D.L., Sirota, M., Cooper, G.M., Sidow, A. and Batzoglou, S. (2010) Identifying a high fraction of the human genome to be under selective constraint using GERP++. *PLoS Comput. Biol.*, **6**, e1001025.
  38. Pollard, K.S., Hubisz, M.J., Rosenbloom, K.R. and Siepel, A. (2010) Detection of nonneutral substitution rates on mammalian phylogenies. *Genome Res.*, **20**, 110–121.
  39. Wang, K., Li, M. and Hakonarson, H. (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.*, **38**, e164.
  40. Danecek, P., Auton, A., Abecasis, G., Albers, C.A., Banks, E., DePristo, M.A., Handsaker, R.E., Lunter, G., Marth, G.T., Sherry, S.T., et al. (2011) The variant call format and VCFtools. *Bioinformatics*, **27**, 2156–2158.
  41. Lane, W.J., Westhoff, C.M., Uy, J.M., Aguad, M., Smeland-Wagman, R., Kaufman, R.M., Rehm, H.L., Green, R.C., Silberstein, L.E. and MedSeq Project (2016) Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle. *Transfusion* , **56**, 743–754.
  42. Yin, Q., Srivastava, K., Brust, D.G. and Flegel, W.A. (2021) Transfusion support during childbirth for a woman with anti-U and the allele. *Immunohematology*, **37**, 1–4.
  43. Lawler, S.D. and Van Loghem, J.J., Jr (1947) The rhesus antigen CW causing haemolytic disease of the newborn. *Lancet*, **2**, 545.
  44. Wester, E.S., Storry, J.R. and Olsson, M.L. (2011) Characterization of Jk(a+(weak)): a new blood group phenotype associated with an altered JK\*01 allele. *Transfusion* , **51**, 380–392.
  45. Wu, P.C., Chyan, T.-W., Feng, S.-H., Chen, M.-H. and Pai, S.-C. (2019) Genotyping and serotyping profiles showed weak Jk presentation for previously typed as Jk donors. *Vox Sang.*, **114**, 268–274.
  46. Huang H.J. and Tagawa H. (1982) [Hemolytic disease of the newborn due to anti-Ku (author's transl)]. *Nihon Sanka Fujinka Gakkai Zasshi*, **34**, 119–121.
  47. Lee, S., Wu, X., Reid, M., Zelinski, T. and Redman, C. (1995) Molecular basis of the Kell (K1) phenotype. Molecular basis of the Kell (K1) phenotype. *Blood* (**1995**) , **85**, 912–916.
  48. Daniels, G., Hadley, A. and Green, C.A. (2003) Causes of fetal anemia in hemolytic disease due to anti-K. *Transfusion* , **43**, 115–116.
  49. Felimban, R.I. and Sumeda, S.M. (2021) Distribution of Kell antigens K, k, Kp, and Kp among blood donors in Jeddah city of Western Saudi Arabia. *Asian J. Transfus. Sci.*, **15**, 75–81.

50. Alalshaikh, M., Almalki, Y., Hasanato, R., Almomen, A., Alsughayir, A., Alabdullateef, A., Sabbar, A. and Alsuhaibani, O. (2021) Frequency of Rh and K antigens in blood donors in Riyadh. Frequency of Rh and K antigens in blood donors in Riyadh. *Hematology, Transfusion and Cell Therapy* (2021).
51. Vendrame, T.A.P., Silva, F.S.A., Aravechia, M.G., Santos, L.D., Costa, T.H., Sirianni, M.F.M., Pedro, T., Cortez, A.J.P., Castilho, L., Latini, F., et al. (2021) ANTI-CRA: A FAMILY STUDY OF A BRAZILIAN FAMILY IN MOLECULAR TIMES. ANTI-CRA: A FAMILY STUDY OF A BRAZILIAN FAMILY IN MOLECULAR TIMES. *Hematology, Transfusion and Cell Therapy* (2021), 43, S314–S315.
52. Kwon, M.Y., Su, L., Arndt, P.A., Garratty, G. and Blackall, D.P. (2004) Clinical significance of anti-Jra: report of two cases and review of the literature. *Transfusion*, 44, 197–201.
53. Peyrard, T., Pham, B.-N., Arnaud, L., Fleutiaux, S., Brossard, Y., Guerin, B., Desmoulin, I., Rouger, P. and Le Pennec, P.-Y. (2008) Fatal hemolytic disease of the fetus and newborn associated with anti-Jra. Fatal hemolytic disease of the fetus and newborn associated with anti-Jra. *Transfusion* (2008), 48, 1906–1911.
54. Levene, C., Sela, R., Dvilansky, A., Yermiahu, T. and Daniels, G. (1986) The Jr(a-) phenotype and anti-Jra in two Beduin Arab women in Israel. The Jr(a-) phenotype and anti-Jra in two Beduin Arab women in Israel. *Transfusion* (1986), 26, 119–120.
55. Liu, S., Ajne, G., Wikman, A., Lindqvist, C., Reilly, M. and Tiblad, E. (2021) Management and clinical consequences of red blood cell antibodies in pregnancy: A population-based cohort study. *Acta Obstet. Gynecol. Scand.*, 100, 2216–2225.
56. Sheeladevi, C.S., Suchitha, S., Manjunath, G.V. and Murthy, S. (2013) Hemolytic Disease of the Newborn Due to Anti-c Isoimmunization: A Case Report. *Indian J. Hematol. Blood Transfus.*, 29, 155–157.
57. Shastry, S. and Bhat, S. (2014) Severe hemolytic disease of newborn in a rh d-positive mother: time to mandate the antenatal antibody screening. *J. Obstet. Gynaecol. India*, 64, 291–292.
58. Flesch, B.K., Scherer, V., Just, B., Opitz, A., Ochmann, O., Janson, A., Steitz, M. and Zeiler, T. (2020) Molecular Blood Group Screening in Donors from Arabian Countries and Iran Using High-Throughput MALDI-TOF Mass Spectrometry and PCR-SSP. *Transfus. Med. Hemother.*, 47, 396–408.
59. [No title]  
<https://www.jrmds.in/articles/abo-and-rhesus-blood-groups-distribution-in-healthy-individuals-an-update-cross-sectional-study-from-tertiary-care-cente.pdf> (accessed Mar 21, 2022).
60. Elsayid, M., Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences and Riyadh (2017) Phenotypic Profile of Kell Blood Group System among Saudi Donors at King Abdulaziz Medical City-Riyadh. Phenotypic Profile of Kell Blood Group System among Saudi Donors at King Abdulaziz Medical City-Riyadh. *Journal of Medical Science And clinical Research* (2017), 05, 15654–15657.
61. Sajwani, F.H., Amer, A.M., Khamis, F.M. and AlShamsi, S.R. (2021) Prevalence of major blood group antigens in blood donors at a main donation center in United Arab Emirates. Prevalence of major blood group antigens in blood donors at a main donation center in United Arab Emirates. *Immunohematology* (2021), 37, 171–177.
62. Lee, S., Wu, X., Reid, M. and Redman, C. (2003) Molecular basis of the K:6,-7 [Js(a b-)] phenotype in the Kell blood group system. Molecular basis of the K:6,-7 [Js(a b-)] phenotype in the Kell blood group system. *Transfusion* (2003), 35, 822–825.

63. Williams, T.N. and Weatherall, D.J. (2012) World distribution, population genetics, and health burden of the hemoglobinopathies. *Cold Spring Harb. Perspect. Med.*, **2**, a011692.
64. Al-Jawaldeh, A., Taktouk, M., Doggui, R., Abdollahi, Z., Achakzai, B., Aguenou, H., Al-Halaika, M., Almamary, S., Barham, R., Coulibaly-Zerbo, F., et al. (2021) Are Countries of the Eastern Mediterranean Region on Track towards Meeting the World Health Assembly Target for Anemia? A Review of Evidence. *Int. J. Environ. Res. Public Health*, **18**.
65. El-Hazmi, M.A.F., Al-Hazmi, A.M. and Warsy, A.S. (2011) Sickle cell disease in Middle East Arab countries. *Indian J. Med. Res.*, **134**, 597–610.
66. Hindawi, S. (2020) Evolution of Blood Transfusion Medicine in Saudi Arabia. *Transfusion*, **60 Suppl 1**, S2–S3.